Loading…
Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study
•The optimal duration of metronomic chemotherapy (MTCD) as adjuvant chemotherapy in patients with locally advanced NPC could be recommended for > 3 months.•MTCD as adjuvant chemotherapy was an independent factor affecting OS, PFS, and DMFS prognosis.•Metronomic adjuvant chemotherapy was mildly to...
Saved in:
| Published in: | Oral oncology 2024-09, Vol.156, p.106908, Article 106908 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453 |
| container_end_page | |
| container_issue | |
| container_start_page | 106908 |
| container_title | Oral oncology |
| container_volume | 156 |
| creator | Dong, Shuhui Bei, Weixin Lin, Lanfeng Jiang, Yaofei Lu, Nian Liu, Guoying Xiang, Yanqun Xia, Weixiong |
| description | •The optimal duration of metronomic chemotherapy (MTCD) as adjuvant chemotherapy in patients with locally advanced NPC could be recommended for > 3 months.•MTCD as adjuvant chemotherapy was an independent factor affecting OS, PFS, and DMFS prognosis.•Metronomic adjuvant chemotherapy was mildly toxic and tolerable.
This retrospective study aimed to determine the optimal metronomic chemotherapy duration (MTCD) as adjuvant therapy for patients with locally advanced nasopharyngeal carcinoma (LANPC).
This study involved LANPC patients treated with metronomic chemotherapy (MTC) using a 5-FU prodrug (S1, capecitabine, or tegafur) from May 2013 to September 2020. The optimal MTCD threshold was established using X-tile Bioinformatics software. The overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) were compared between short-term and long-term groups using propensity score matching (PSM).
A total of 546 patients were analyzed. MTCD was an independent prognostic factor for OS, PFS, and DMFS (all P 3 months) and short-term (≤3 months) MTCD groups. After a median follow-up of 48 months, significant differences were observed in 4-year OS (97.0 % vs. 87.1 %; P |
| doi_str_mv | 10.1016/j.oraloncology.2024.106908 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3073230107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837524002264</els_id><sourcerecordid>3073230107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453</originalsourceid><addsrcrecordid>eNqNkc-O1DAMxiMEYpeBV0ARJy4dnKZp072tdvknrcQBOEeZxDOTUdqUJB3UF-F5yagL4sjJlv3z5zgfIW8YbBmw9t1pG6L2YTTBh8OyraFuSqPtQT4h10x2fQWi509LzltZSd6JK_IipRMACCbgObnisuctQHdNfn09hpirjHGgZ4xpTrQoH9bCgDmGMQzOUG1P81mPmZojDiEfMeppoW4stNHeLwUobYOWjjqF6ajjMh5Qe2p0NK5o6Bt6S6cYJhyTywtNJkSsBp2LoKWxoNXPEL2lKc92eUme7bVP-Ooxbsj3D--_3X2qHr58_Hx3-1AZziBXiI0GrSU0IFpppURrWGN0bRq9AykkCIn7xnRtX7c72dl-39VCtIxrZLIRfEPerrrlZT9mTFkNLhn0Xo8Y5qQ4dLzmwErYkJsVNTGkFHGvpuiGcqdioC6-qJP61xd18UWtvpTh14975t2A9u_oHyMKcL8CWK49O4wqGYeXD3URTVY2uP_Z8xviGKos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073230107</pqid></control><display><type>article</type><title>Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study</title><source>ScienceDirect Journals</source><creator>Dong, Shuhui ; Bei, Weixin ; Lin, Lanfeng ; Jiang, Yaofei ; Lu, Nian ; Liu, Guoying ; Xiang, Yanqun ; Xia, Weixiong</creator><creatorcontrib>Dong, Shuhui ; Bei, Weixin ; Lin, Lanfeng ; Jiang, Yaofei ; Lu, Nian ; Liu, Guoying ; Xiang, Yanqun ; Xia, Weixiong</creatorcontrib><description><![CDATA[•The optimal duration of metronomic chemotherapy (MTCD) as adjuvant chemotherapy in patients with locally advanced NPC could be recommended for > 3 months.•MTCD as adjuvant chemotherapy was an independent factor affecting OS, PFS, and DMFS prognosis.•Metronomic adjuvant chemotherapy was mildly toxic and tolerable.
This retrospective study aimed to determine the optimal metronomic chemotherapy duration (MTCD) as adjuvant therapy for patients with locally advanced nasopharyngeal carcinoma (LANPC).
This study involved LANPC patients treated with metronomic chemotherapy (MTC) using a 5-FU prodrug (S1, capecitabine, or tegafur) from May 2013 to September 2020. The optimal MTCD threshold was established using X-tile Bioinformatics software. The overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) were compared between short-term and long-term groups using propensity score matching (PSM).
A total of 546 patients were analyzed. MTCD was an independent prognostic factor for OS, PFS, and DMFS (all P < 0.05). Patients were categorized into long-term (>3 months) and short-term (≤3 months) MTCD groups. After a median follow-up of 48 months, significant differences were observed in 4-year OS (97.0 % vs. 87.1 %; P < 0.01), PFS (84.6 % vs. 70.9 %; P < 0.01), DMFS (87.3 % vs. 78.8 %; P < 0.01), and LRRFS (95.3 % vs. 87.4 %; P < 0.01) between the long-term and short-term groups. In the PSM-matched cohort of 196 patients per group, the long-term group demonstrated superior 4-year OS and LRRFS (97.3 % vs. 87.1 %, P < 0.01; 95.2 % vs. 90.0 %, P < 0.05). No significant differences in acute toxicities were observed between the groups (P > 0.05).
Extended MTC with a 5-FU prodrug (>3 months) may benefit NPC patients. Further prospective studies are needed to validate these findings.]]></description><identifier>ISSN: 1368-8375</identifier><identifier>ISSN: 1879-0593</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2024.106908</identifier><identifier>PMID: 38936007</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>5-FU prodrug ; Adjuvant chemotherapy ; Administration, Metronomic ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Capecitabine - administration & dosage ; Capecitabine - therapeutic use ; Chemotherapy, Adjuvant - methods ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; Humans ; Male ; Metronomic chemotherapy ; Middle Aged ; Nasopharyngeal carcinoma ; Nasopharyngeal Carcinoma - drug therapy ; Nasopharyngeal Carcinoma - mortality ; Nasopharyngeal Carcinoma - pathology ; Nasopharyngeal Neoplasms - drug therapy ; Nasopharyngeal Neoplasms - mortality ; Nasopharyngeal Neoplasms - pathology ; Optimal duration ; Propensity Score ; Retrospective Studies</subject><ispartof>Oral oncology, 2024-09, Vol.156, p.106908, Article 106908</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453</citedby><cites>FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38936007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Lin, Lanfeng</creatorcontrib><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Liu, Guoying</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><title>Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description><![CDATA[•The optimal duration of metronomic chemotherapy (MTCD) as adjuvant chemotherapy in patients with locally advanced NPC could be recommended for > 3 months.•MTCD as adjuvant chemotherapy was an independent factor affecting OS, PFS, and DMFS prognosis.•Metronomic adjuvant chemotherapy was mildly toxic and tolerable.
This retrospective study aimed to determine the optimal metronomic chemotherapy duration (MTCD) as adjuvant therapy for patients with locally advanced nasopharyngeal carcinoma (LANPC).
This study involved LANPC patients treated with metronomic chemotherapy (MTC) using a 5-FU prodrug (S1, capecitabine, or tegafur) from May 2013 to September 2020. The optimal MTCD threshold was established using X-tile Bioinformatics software. The overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) were compared between short-term and long-term groups using propensity score matching (PSM).
A total of 546 patients were analyzed. MTCD was an independent prognostic factor for OS, PFS, and DMFS (all P < 0.05). Patients were categorized into long-term (>3 months) and short-term (≤3 months) MTCD groups. After a median follow-up of 48 months, significant differences were observed in 4-year OS (97.0 % vs. 87.1 %; P < 0.01), PFS (84.6 % vs. 70.9 %; P < 0.01), DMFS (87.3 % vs. 78.8 %; P < 0.01), and LRRFS (95.3 % vs. 87.4 %; P < 0.01) between the long-term and short-term groups. In the PSM-matched cohort of 196 patients per group, the long-term group demonstrated superior 4-year OS and LRRFS (97.3 % vs. 87.1 %, P < 0.01; 95.2 % vs. 90.0 %, P < 0.05). No significant differences in acute toxicities were observed between the groups (P > 0.05).
Extended MTC with a 5-FU prodrug (>3 months) may benefit NPC patients. Further prospective studies are needed to validate these findings.]]></description><subject>5-FU prodrug</subject><subject>Adjuvant chemotherapy</subject><subject>Administration, Metronomic</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Capecitabine - administration & dosage</subject><subject>Capecitabine - therapeutic use</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Metronomic chemotherapy</subject><subject>Middle Aged</subject><subject>Nasopharyngeal carcinoma</subject><subject>Nasopharyngeal Carcinoma - drug therapy</subject><subject>Nasopharyngeal Carcinoma - mortality</subject><subject>Nasopharyngeal Carcinoma - pathology</subject><subject>Nasopharyngeal Neoplasms - drug therapy</subject><subject>Nasopharyngeal Neoplasms - mortality</subject><subject>Nasopharyngeal Neoplasms - pathology</subject><subject>Optimal duration</subject><subject>Propensity Score</subject><subject>Retrospective Studies</subject><issn>1368-8375</issn><issn>1879-0593</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkc-O1DAMxiMEYpeBV0ARJy4dnKZp072tdvknrcQBOEeZxDOTUdqUJB3UF-F5yagL4sjJlv3z5zgfIW8YbBmw9t1pG6L2YTTBh8OyraFuSqPtQT4h10x2fQWi509LzltZSd6JK_IipRMACCbgObnisuctQHdNfn09hpirjHGgZ4xpTrQoH9bCgDmGMQzOUG1P81mPmZojDiEfMeppoW4stNHeLwUobYOWjjqF6ajjMh5Qe2p0NK5o6Bt6S6cYJhyTywtNJkSsBp2LoKWxoNXPEL2lKc92eUme7bVP-Ooxbsj3D--_3X2qHr58_Hx3-1AZziBXiI0GrSU0IFpppURrWGN0bRq9AykkCIn7xnRtX7c72dl-39VCtIxrZLIRfEPerrrlZT9mTFkNLhn0Xo8Y5qQ4dLzmwErYkJsVNTGkFHGvpuiGcqdioC6-qJP61xd18UWtvpTh14975t2A9u_oHyMKcL8CWK49O4wqGYeXD3URTVY2uP_Z8xviGKos</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Dong, Shuhui</creator><creator>Bei, Weixin</creator><creator>Lin, Lanfeng</creator><creator>Jiang, Yaofei</creator><creator>Lu, Nian</creator><creator>Liu, Guoying</creator><creator>Xiang, Yanqun</creator><creator>Xia, Weixiong</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202409</creationdate><title>Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study</title><author>Dong, Shuhui ; Bei, Weixin ; Lin, Lanfeng ; Jiang, Yaofei ; Lu, Nian ; Liu, Guoying ; Xiang, Yanqun ; Xia, Weixiong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>5-FU prodrug</topic><topic>Adjuvant chemotherapy</topic><topic>Administration, Metronomic</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Capecitabine - administration & dosage</topic><topic>Capecitabine - therapeutic use</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Metronomic chemotherapy</topic><topic>Middle Aged</topic><topic>Nasopharyngeal carcinoma</topic><topic>Nasopharyngeal Carcinoma - drug therapy</topic><topic>Nasopharyngeal Carcinoma - mortality</topic><topic>Nasopharyngeal Carcinoma - pathology</topic><topic>Nasopharyngeal Neoplasms - drug therapy</topic><topic>Nasopharyngeal Neoplasms - mortality</topic><topic>Nasopharyngeal Neoplasms - pathology</topic><topic>Optimal duration</topic><topic>Propensity Score</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Lin, Lanfeng</creatorcontrib><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Liu, Guoying</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Shuhui</au><au>Bei, Weixin</au><au>Lin, Lanfeng</au><au>Jiang, Yaofei</au><au>Lu, Nian</au><au>Liu, Guoying</au><au>Xiang, Yanqun</au><au>Xia, Weixiong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>156</volume><spage>106908</spage><pages>106908-</pages><artnum>106908</artnum><issn>1368-8375</issn><issn>1879-0593</issn><eissn>1879-0593</eissn><abstract><![CDATA[•The optimal duration of metronomic chemotherapy (MTCD) as adjuvant chemotherapy in patients with locally advanced NPC could be recommended for > 3 months.•MTCD as adjuvant chemotherapy was an independent factor affecting OS, PFS, and DMFS prognosis.•Metronomic adjuvant chemotherapy was mildly toxic and tolerable.
This retrospective study aimed to determine the optimal metronomic chemotherapy duration (MTCD) as adjuvant therapy for patients with locally advanced nasopharyngeal carcinoma (LANPC).
This study involved LANPC patients treated with metronomic chemotherapy (MTC) using a 5-FU prodrug (S1, capecitabine, or tegafur) from May 2013 to September 2020. The optimal MTCD threshold was established using X-tile Bioinformatics software. The overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) were compared between short-term and long-term groups using propensity score matching (PSM).
A total of 546 patients were analyzed. MTCD was an independent prognostic factor for OS, PFS, and DMFS (all P < 0.05). Patients were categorized into long-term (>3 months) and short-term (≤3 months) MTCD groups. After a median follow-up of 48 months, significant differences were observed in 4-year OS (97.0 % vs. 87.1 %; P < 0.01), PFS (84.6 % vs. 70.9 %; P < 0.01), DMFS (87.3 % vs. 78.8 %; P < 0.01), and LRRFS (95.3 % vs. 87.4 %; P < 0.01) between the long-term and short-term groups. In the PSM-matched cohort of 196 patients per group, the long-term group demonstrated superior 4-year OS and LRRFS (97.3 % vs. 87.1 %, P < 0.01; 95.2 % vs. 90.0 %, P < 0.05). No significant differences in acute toxicities were observed between the groups (P > 0.05).
Extended MTC with a 5-FU prodrug (>3 months) may benefit NPC patients. Further prospective studies are needed to validate these findings.]]></abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38936007</pmid><doi>10.1016/j.oraloncology.2024.106908</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-8375 |
| ispartof | Oral oncology, 2024-09, Vol.156, p.106908, Article 106908 |
| issn | 1368-8375 1879-0593 1879-0593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3073230107 |
| source | ScienceDirect Journals |
| subjects | 5-FU prodrug Adjuvant chemotherapy Administration, Metronomic Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Capecitabine - administration & dosage Capecitabine - therapeutic use Chemotherapy, Adjuvant - methods Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Humans Male Metronomic chemotherapy Middle Aged Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Carcinoma - mortality Nasopharyngeal Carcinoma - pathology Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - pathology Optimal duration Propensity Score Retrospective Studies |
| title | Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A08%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-term%20versus%20long-term%20metronomic%20adjuvant%20chemotherapy%20in%20locally%20advanced%20nasopharyngeal%20carcinoma:%20A%20propensity%20score-matched%20real-world%20study&rft.jtitle=Oral%20oncology&rft.au=Dong,%20Shuhui&rft.date=2024-09&rft.volume=156&rft.spage=106908&rft.pages=106908-&rft.artnum=106908&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2024.106908&rft_dat=%3Cproquest_cross%3E3073230107%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c310t-ee4a0aa8040568d88edc14ca2c4ab0858058ef4c76926b87d9f7255613ae18453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3073230107&rft_id=info:pmid/38936007&rfr_iscdi=true |